What Does Ketamine Therapy Actually Cost — and Why Does the Price Vary So Much?
The cost of ketamine therapy typically ranges from $400 to $800 per session out of pocket for off-label treatments, while esketamine (Spravato), an FDA-approved nasal spray, is covered by most major insurers and often reduces patient costs to a standard office visit co-pay.
If you've spent time researching ketamine for depression, you've likely encountered a confusing landscape of pricing. Some organizations quote $500 per session. Others advertise packages of six sessions for $3,000 or more. And then there's esketamine (Spravato) — which some patients report paying standard co-pays for, while others wonder whether it's covered at all. The inconsistency is not accidental. It reflects a deeper structural divide between off-label and FDA-approved treatment pathways — one that shapes not only what you pay, but how your care is monitored, sustained, and supported over time.
This article is not a price sheet. It's a framework for understanding why these costs differ, what each pathway includes (and excludes), and how to evaluate the true financial picture of treatment — including hidden costs that rarely appear on a billing statement.
The Structural Reason Prices Diverge: Off-Label vs. FDA-Approved
Before comparing specific dollar amounts, it helps to understand the regulatory architecture that creates the price gap in the first place.
Off-label ketamine is a legal, evidence-based application of a medicine that has been in clinical use for over 50 years, and its only FDA-approved indication is for anesthesia. When it is prescribed for depression, anxiety, or other psychiatric conditions, it falls outside the scope of what most commercial insurance plans will cover. That means the full cost of treatment — the medication, the clinical monitoring, the provider's time — is borne by the patient. At Lumin Health, we provide Intramuscular (IM) ketamine injections, highlighting benefits like speed and comfort compared to a slow IV infusion.
Esketamine (Spravato), by contrast, went through the FDA's formal approval process and is FDA-approved for adults with treatment-resistant depression and major depression with suicidal thoughts. Because it carries FDA approval, insurance companies have established coverage policies for it. The result is a fundamentally different financial experience for the patient.
This distinction is not a judgment about which treatment is "better." Both act on the brain's glutamate system. Off-label ketamine is a racemic mixture containing both the S-ketamine and R-ketamine molecules, whereas esketamine (Spravato) uses the more active S-enantiomer (the "s" stands for sinistrum, Latin for "left," as the esketamine molecule is oriented to the left). Both may promote neuroplasticity — helping the brain form new connections and easing the rigid, entrenched patterns that characterize chronic depression. But the financial infrastructure surrounding each is substantially different, and that difference shapes access in ways that matter.
IV and IM Ketamine Prices: What Patients Typically Pay Out of Pocket
The IV ketamine price and IM ketamine price at most practices in the United States range from approximately $400 to $800 per individual session. Some organizations bundle sessions — a common model is six sessions over two to three weeks — with package pricing that can run between $2,400 and $4,800 or more.
Here's what those costs generally include:
- The ketamine medication itself
- Clinical monitoring during and after the session (vital signs, pulse oximetry)
- Psychiatric care and oversight for the duration of the session
- Use of the treatment space and any comfort amenities
Here's what those costs generally do not include:
- The initial comprehensive evaluation to determine candidacy
- Follow-up visits to assess response, adjust dosing, or discuss next steps
- Any concurrent medications or psychotherapy the patient may be engaged in independently
- Maintenance sessions — which many patients need on an ongoing basis to sustain benefit
At Lumin Health, our Intramuscular (IM) ketamine sessions are priced at $500 per session. IM delivery offers predictable absorption and is administered similarly to a standard injection, without requiring an IV line. Most commercial insurers do not cover off-label ketamine treatment for mental health indications. However, Lumin Health provides a Superbill — an itemized receipt — for patients with out-of-network PPO benefits to submit for potential partial reimbursement.
The cumulative cost is the part that often catches patients off guard. A standard induction course of six sessions at $500 each totals $3,000. If maintenance sessions are needed monthly or bimonthly thereafter, the annual cost can climb substantially. For many families, this creates a real barrier — not because the treatment lacks merit, but because the financial model was never designed to support long-term psychiatric care.
Esketamine (Spravato) Cost: What Insurance Coverage Actually Looks Like
The esketamine (Spravato) cost conversation begins differently. Because esketamine (Spravato) is FDA-approved for specific psychiatric indications, it is covered by most major commercial insurance plans. At Lumin Health, accepted plans include Aetna, Anthem, Blue Cross Blue Shield, Cigna, Evernorth, Mass General Brigham Health Plan, Harvard Pilgrim, Optum, Point32Health, United Healthcare, and Medicare. Some Tufts plans are also accepted, though not Health Together, Health Direct, OneCare, or ConnectorCare.
With insurance, the cost of esketamine (Spravato) treatment typically aligns with a standard office visit co-pay. We encourage you to check with your insurer or use our eligibility form at lumin.health/insurance-we-accept to understand your specific benefits. For many patients, the per-session cost is a fraction of the out-of-pocket cost of off-label ketamine.
The magnitude of the difference is worth stating plainly: where a course of IM ketamine might cost thousands out of pocket, a comparable course of esketamine (Spravato) under insurance may cost significantly less.
What does the insurance-covered model include?
- The medication itself, delivered intranasally under clinical supervision
- A mandatory two-hour post-dose observation period with vital sign monitoring
- Ongoing treatment within a REMS-certified practice (a federal safety requirement)
- A structured dosing schedule — typically twice weekly during a four-week induction phase, then weekly or every other week for maintenance
The REMS (Risk Evaluation and Mitigation Strategy) certification is a detail worth pausing on. It means every practice that administers esketamine (Spravato) has met specific federal standards for patient monitoring and safety. This adds a layer of clinical rigor that is built into the treatment model — and built into the insurance coverage.
The Hidden Costs That Billing Statements Don't Show
A transparent cost comparison requires looking beyond the per-session price tag. There are real, material costs associated with ketamine therapy that rarely appear on a receipt but shape the financial experience of treatment.
Time away from work. Both IM ketamine and esketamine (Spravato) require in-person visits. During induction, esketamine (Spravato) patients may visit twice per week. IM ketamine patients typically complete two to three sessions per week during their initial course. Each visit involves travel, treatment time, the observation period, and recovery. For hourly workers or those without paid leave, this represents a meaningful financial impact.
Transportation. After any ketamine treatment session, you cannot drive for the remainder of the day. This means arranging a ride — whether through a partner, family member, or ride-share service — for every session. Over a course of treatment, these costs accumulate.
The cost of not responding. This is perhaps the most underappreciated financial dimension. For patients who have cycled through multiple antidepressant trials over years — each requiring months to evaluate — the cumulative cost of lost productivity, strained relationships, and diminished quality of life is substantial. Research from the STAR*D trial demonstrated that after several courses that haven't provided relief, the likelihood of response to another traditional medication falls significantly. By contrast, while there are no guarantees, clinical evidence suggests ketamine therapy and esketamine (Spravato) may help create a biologically receptive window for change, offering meaningful relief for many who did not respond to previous treatments.
Maintenance over time. Neither ketamine nor esketamine is typically a one-time intervention. Most patients benefit from ongoing maintenance. The long-term financial picture depends heavily on whether those maintenance sessions are covered by insurance or paid out of pocket. Long-term safety data for ketamine and esketamine underscores the importance of sustained, monitored treatment — which in turn requires sustained financial access.
Is Esketamine (Spravato) Expensive? The Answer Depends on Your Vantage Point
The question regarding whether esketamine is expensive gets asked frequently — and the answer reveals something important about how we evaluate cost in mental health care.
At list price — without insurance — a single dose of esketamine (Spravato) carries a manufacturer cost that is substantial. But the list price is not what most patients pay. With commercial insurance, out-of-pocket costs are typically modest. Additionally, the manufacturer offers a savings program that may further reduce costs for eligible patients with private insurance.
The more honest framing may be this: is esketamine expensive relative to what? Relative to a generic SSRI? Yes. Relative to the aggregate cost of years of treatment-resistant depression — the emergency department visits, the lost wages, the sequential medication trials, the declining function — the calculus looks very different.
"I just don't want to feel this way and I don't want to wait for months and months and months to feel better. That's what treatment-resistant means in real human terms."
— Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health
This is not a dismissal of cost concerns. Financial burden is real, and no one should feel pressured into a treatment they cannot afford. But it is an invitation to consider the full financial picture — not just the per-dose price, but the trajectory of illness and the cost of continued suffering.
Why the FDA-Approved Pathway Changes the Insurance Equation
The reason esketamine (Spravato) can be covered by insurance while off-label ketamine generally cannot comes down to a regulatory reality that shapes all of American medicine: insurance companies build coverage policies around FDA-approved indications.
When a drug receives FDA approval for a specific condition, insurers develop medical policies, prior authorization criteria, and coverage pathways. For esketamine (Spravato), this means:
- Patients with treatment-resistant depression — generally defined as depression that has not responded to at least two adequate courses of antidepressant treatment — can qualify for coverage through the TRD pathway
- Patients with major depressive disorder and active suicidal ideation can qualify through the MDDSSI pathway, which does not require prior courses that haven't provided relief
- Each insurance company adds its own nuance to how TRD is defined, requiring expertise from a medical organization to navigate the authorization process
At Lumin Health, insurance verification is conducted upfront. The goal is to provide clarity before treatment begins — not after a bill arrives. You can check your coverage through our insurance eligibility page or by contacting the practice directly.
For off-label ketamine, the insurance landscape is less accommodating. Because there is no FDA-approved psychiatric indication for racemic ketamine — the mixture containing both the S-ketamine and R-ketamine molecules — most commercial plans treat it as an excluded service. Some patients with out-of-network PPO benefits may recover a portion of costs through Superbill submission, but this is not guaranteed and varies widely by plan.
Clinical Considerations That Influence Which Path Makes Sense
Cost is one factor in treatment selection — but it is not the only one. The clinical decision between off-label ketamine and esketamine (Spravato) involves several additional considerations that our academically-affiliated, psychiatrist-led team evaluates on a case-by-case basis.
Indication. Esketamine (Spravato) is FDA-approved for adults with treatment-resistant depression and major depression with suicidal thoughts. Patients who fall outside those indications may find that off-label ketamine is the more appropriate clinical pathway, even if it means paying out of pocket.
Route of administration. Esketamine (Spravato) is delivered intranasally in a standardized spray designed for predictable mucosal absorption. At Lumin Health, we provide Intramuscular (IM) ketamine injections, highlighting its benefits such as speed and comfort compared to a slow IV infusion. Both routes offer reliable delivery, but the experience and logistics differ. Some patients have strong preferences about one over the other.
Prior medication history. For esketamine (Spravato) coverage through the TRD pathway, most insurers require documentation of prior antidepressant trials. Patients who have not yet tried — or cannot document — two prior adequate trials may face authorization challenges. This is a logistical reality, not a clinical one.
Speed and access. At Lumin Health, based out of the Boston Metro area and expanding to other states, most patients can begin treatment within approximately two weeks of their initial call. The specific timeline depends on insurance verification (for Spravato) or scheduling (for IM ketamine). Both pathways begin with a comprehensive psychiatric evaluation — not merely a checklist, but a genuine clinical assessment of fit, safety, and goals.
Both ketamine therapy and esketamine (Spravato) act on the glutamate system, which may trigger the downstream release of Brain-Derived Neurotrophic Factor (BDNF) — a growth factor that helps the brain form new connections. This is the biological basis of the neuroplasticity window that patients and clinicians alike reference when discussing how these treatments create conditions for change. The Default Mode Network — the brain's self-referential thinking hub, which in depression can become rigid and overactive — may quiet during treatment, allowing patients to experience old patterns with less automatic negativity. These mechanisms are shared between both pathways. The question of cost is, in many ways, a question of access to the same underlying biology.
A Note on MassHealth and Uninsured Patients
Lumin Health is out-of-network for MassHealth. For patients covered by MassHealth, ketamine treatment would be fully out of pocket. This is an important limitation to name directly, because transparency about access is as important as transparency about pricing.
For uninsured patients or those whose plans do not cover either pathway, the financial picture is more challenging. Some patients choose to pursue IM ketamine at the per-session rate, sometimes completing a focused induction course and then spacing maintenance sessions based on clinical response and budget. Others may explore whether they qualify for commercial insurance plans that do cover esketamine (Spravato) during open enrollment periods.
There is no single right answer here — only the answer that fits your circumstances, your clinical needs, and your financial reality.
Frequently Asked Questions
How much does a full course of IM ketamine cost without insurance?
A typical induction course of six sessions ranges from $2,400 to $4,800 or more depending on the provider. At Lumin Health, IM ketamine sessions are $500 each. Maintenance sessions — often needed monthly or bimonthly — add to the long-term cost. These figures do not include the initial evaluation or follow-up appointments.
Is esketamine (Spravato) covered by my insurance?
Esketamine (Spravato) is covered by most major commercial insurance plans. Coverage typically requires meeting specific clinical criteria — most commonly, a diagnosis of treatment-resistant depression or major depressive disorder with suicidal ideation. Lumin Health verifies insurance eligibility before treatment begins. You can check your plan at lumin.health/insurance-we-accept.
Why can't insurance cover off-label ketamine the same way it covers Spravato?
Insurance coverage is built around FDA-approved indications. Ketamine's only FDA-approved use is for anesthesia — its psychiatric applications are off-label. Esketamine (Spravato) went through the formal FDA approval process for adults with treatment-resistant depression and major depression with suicidal thoughts, which is why insurers have established coverage pathways for it.
What if I can't afford either option?
If cost is a barrier, it is worth exploring several avenues: checking whether your insurance covers esketamine (Spravato), reviewing out-of-network PPO benefits for potential partial reimbursement of IM ketamine, or discussing a paced treatment plan with your clinical team. At Lumin Health, based out of the Boston Metro area and expanding to other states, these conversations happen early — because financial sustainability is part of responsible treatment planning.
Does a higher price mean better treatment?
No. The price of ketamine therapy reflects regulatory status and insurance infrastructure — not clinical quality. What matters is whether treatment is delivered in a medically supervised setting by academically-affiliated providers specifically trained in ketamine and esketamine, with appropriate monitoring, psychiatric care, and behavioral support. The most expensive session in a poorly monitored environment is not superior to an insurance-covered session delivered with clinical rigor.
If you are exploring whether this may be a fit and want clarity about what treatment might look like — financially and clinically — Lumin Health welcomes that conversation. We would be grateful to walk with you through the specifics of your situation, your coverage, and your goals, so that cost does not remain a barrier to exploring relief. You can reach us at 617-863-8810 or explore more at lumin.health/ketamine-and-esketamine.
Find out if ketamine therapy is covered by your plan.
Lumin Health accepts most major insurance providers for Spravato treatment in Massachusetts and the greater Washington DC/Maryland area. Use our free tool to check your coverage instantly — no forms, no phone calls.
Available in Massachusetts and the greater Washington DC/Maryland area.
.svg)
